June 25, 2024

Holistic Pulse

Healthcare is more important

Is Fibromyalgia an Autoimmune Disease?

9 min read
Autoantibody Rates, FM Studies
Serotonin 73%
Gangliosides 71%
Phospholipids 54%
Smooth muscle 55%
Striated muscle 40%
Sjögren’s syndrome antibodies 32%
Thyroid gland 19%
*Among those with Sjögren’s syndrome

Giving Fibromyalgia to Mice

In a groundbreaking 2021 study, researchers took antibodies (immunoglobulin G, IgG) from people with FM and injected them into mice. The mice then:

  • Developed hypersensitivity to pain and cold
  • Became less active
  • Lost paw grip strength
  • Lost nerve fibers in the skin

Researchers say the FM IgG appeared to target white-matter brain cells (glia), gray-matter brain cells (neurons), and certain nerve fibers. This shows how immune system activity can cause neurological symptoms.

The ability to transfer FM like this is nothing short of revolutionary. On top of providing evidence about what’s causing symptoms, it could point to new diagnostic tests and treatments.

Diagnosis and Treatment

If more research validates findings of autoimmunity in fibromyalgia, it could lead to diagnostic tests. Because fibromyalgia is currently a diagnosis of exclusion, that would be an important change.

A 2022 study focused on identifying biomarkers for diagnosing and managing fibromyalgia, found that study participants with FM had elevated levels of 19 inflammatory serum proteins, indicating widespread inflammation.

Many immunosuppressive drugs for autoimmune diseases are already on the market. That greatly expands treatment options, especially since the drugs could be used off-label right away.

Whether current immunosuppressants are safe and effective for FM remains to be seen.


Several studies have now confirmed neuroinflammation in fibromyalgia. Some also have looked at where it is in the brain and what may be driving it.

Inflammation is a complex immune response to injury and infection. It’s a necessary function. But when it becomes chronic, inflammation causes tissue damage. It’s especially harmful to the nervous system.

Verywell / Shideh Ghandeharizadeh

The nervous system and immune system work together to create neuroinflammation. FM research links several cells and one molecule to the process.

Neurological components include:

  • Microglia: A type of cell that’s part of the nervous system’s dedicated immune system
  • Astrocytes: Cells of the brain and spinal cord involved in information processing and implicated in neurodegenerative disease
  • Oligodendrocytes: White-matter cells that form myelin sheaths around nerves and regulate neuronal circuits
  • Brain-derived neurotrophic factor (BDNF): A key molecule involved in learning and memory, also tied to aging and brain-related disease

Immune system components include:

  • Mast cells: A type of white blood cell that helps keep the immune system in balance
  • Chemokines: Immune cells that attract white blood cells to sites of infection
  • Pro-inflammatory cytokines: Immune system proteins that drive the inflammatory response
  • Interleukins: Proteins that regulate immune response
  • Tumor necrosis factor alpha (TNFα): A type of cytokine involved in inflammation and cell death
  • Macrophages: Tissue-resident immune cells usually found at the site of infection
  • T-cells: Specialized immune cells that target proteins identified (or misidentified) as foreign

A 2021 study looked at where brain inflammation is in FM. Researchers found several areas with abnormal inflammation compared with healthy people in the control group.

Some of these areas play roles in functions that are often dysregulated in people with FM. They include:

  • Primary somatosensory cortex: Processes physical sensations, especially touch
  • Primary motor cortex: Skilled movement
  • Superior frontal gyrus: Higher cognitive function and working memory
  • Left superior parietal gyrus: Attention, spatial perception
  • Left precuneus: Memory-based tasks, episodic memory recall
  • Left medial frontal gyrus: Development of literacy

They also found abnormally low inflammation-related activity in the:

  • Medulla: Relays messages between the brain and spinal cord, regulates cardiovascular and respiratory systems (heart and lungs)
  • Amygdala: Drives the stress and fear response (fight-or-flight)
  • Left superior temporal gyrus: Language processing, remembering what you’ve just heard

Neuroinflammation in the amygdala, left medial frontal, and left superior parietal gyri was associated with higher pain scores. Neuroinflammation in the left amygdala, left medial frontal, and left superior frontal gyri was associated with higher stress responses, which included measures of fatigue, tension, frustration, depression, somatization, and aggression.

A Different Type of Inflammation

Neuroinflammation has different effects than “typical” inflammation in the joints and soft tissues. Typical inflammation causes pain in many conditions, such as arthritis and multiple sclerosis.

When tissues expand beyond their normal size, they cause pain by putting pressure on surrounding structures. Arthritic fingers hurt because they’re inflamed.

Neuroinflammation doesn’t cause the same issues. Instead, it causes neurological problems that lead to neurological symptoms.

FM pain is believed to come from central sensitization, which is a heightened response to pain in the central nervous system. Research suggests neuroinflammation is behind central sensitization.

So, regardless of neuroinflammation, your FM pain isn’t caused by tissue inflammation and therefore can’t be treated in the same way.

Inflammatory markers for fibromyalgia tend to be slightly elevated. However, the cells and molecules involved in the neuroinflammation of FM may provide new diagnostic markers to look for.

Diagnosis and Treatment

Drugs that suppress microglia and astrocytes may be useful for treating neuroinflammation. They include:

  • Low-dose naltrexone (LDN)
  • Diamox (acetazolamide)
  • Trental/Pentoxil (pentoxifylline)
  • Zirgan (ganciclovir)
  • Rifadin (rifampin)
  • Enbrel (etanercept)
  • Precedex (dexmedetomidine)
  • Delsym/Robitussin (dextromethorphan)
  • Propentofylline (an experimental drug)
  • Dynacin/Minocin/Solodyn (minocycline)
  • Cannabidiol (CBD)
  • P2X7R inhibitors (experimental drugs)

Other existing treatments for neuroinflammation include: 

Several other drugs are under development for neuroinflammation, most of them developed as potential Parkinson’s disease treatments. Anti-inflammatory drugs are often prescribed for neuroinflammatory diseases as well. However, they’ve historically been considered ineffective for FM pain.

Small-Fiber Neuropathy

Small-fiber neuropathy (SFN) is nerve damage that’s only in the small sensory nerves of the skin. It’s probably best known in association with type 2 diabetes.

As in FM, the pain comes and goes and is described as:

  • Stabbing
  • Burning
  • Tingling
  • Itchy

Also like FM, SFN involves the abnormal pain types hyperalgesia and allodynia. Hyperalgesia makes your pain signals more intense, basically “turning up the volume” of pain. Allodynia makes things hurt that shouldn’t, like a loose waistband or a hand rubbing lightly against your skin.

SFN and fibromyalgia also have these symptoms in common:

FM research suggests some damaged nerves are part of anti-inflammatory processes. That provides another explanation for neuroinflammation.

Typical SFN vs. Fibromyalgia SFN

In most SFN, pain begins in the feet and then moves upward. It’s been thought that only a small percentage of SFN begins with body-wide pain. The association between SFN and FM, which by definition includes body-wide pain, could change that belief.

Diagnosis and Treatment

The typical diagnostic test for SFN is a skin punch biopsy. A small amount of skin is removed with a circular tool and examined under a microscope. The focus is on nerve fiber density in the skin.

SFN is treatable, and small nerves continue to grow throughout life. That means they can repair the damage.

Standard SFN treatments are already heavily used for fibromyalgia. They include:

  • Anti-seizure medications: Lyrica (pregabalin), Neurontin (gabapentin)
  • Serotonin-norepinephrine reuptake inhibitors: Cymbalta (duloxetine), venlafaxine
  • Tricyclic antidepressants: Amitriptyline, nortriptyline, desipramine

In a pilot study, treatment with intravenous immunoglobulin (IVIg) has been shown to improve SFN in FM. This treatment is known to be effective against autoimmune-related neuropathy. Biopsies confirmed that nerves showed less damage after treatment.

Ganglioside autoimmunity may suggest treatment options as well. Gangliosides are suspected of being involved with diabetes-related small-fiber neuropathy. Some early animal research has suggested that ganglioside-targeted treatments may improve neuropathic pain.

Currently, researchers are working on drugs called ganglioside GM3 synthase inhibitors. Evidence suggests that these may work as both oral medication and topical treatments.


Research has uncovered evidence that FM is an autoimmune disease. Neuroinflammation and small-fiber neuropathy appear to be important elements of it. Autoantibodies could provide diagnostic markers for FM. Immunosuppressants may be treatment options. Neuroinflammation and SFN also offer potential diagnostic markers. Existing treatments are on the market. Some experimental drugs are in the works as well.

Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial process to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Goebel A, Krock E, Gentry C, et al. Passive transfer of fibromyalgia symptoms from patients to mice. J Clin Invest. 2021;131(13):e144201. doi:10.1172/JCI144201

  2. Ryabkova VA, Churilov LP, Shoenfeld Y. Neuroimmunology: what role for autoimmunity, neuroinflammation, and small fiber neuropathy in fibromyalgia, chronic fatigue syndrome, and adverse events after human papillomavirus vaccination? Int J Mol Sci. 2019;20(20):5164. doi:10.3390/ijms20205164

  3. National Institute of Environmental Health Sciences. Autoimmune diseases.

  4. Inanici F, Yunus MB. History of fibromyalgia: past to present. Curr Pain Headache Rep. 2004;8(5):369-378. doi:10.1007/s11916-996-0010-6

  5. Sipione S, Monyror J, Galleguillos D, Steinberg N, Kadam V. Gangliosides in the brain: physiology, pathophysiology and therapeutic applications. Front Neurosci. 2020;14:572965. doi:10.3389/fnins.2020.572965

  6. Suk JH, Lee JH, Kim JM. Association between thyroid autoimmunity and fibromyalgia. Exp Clin Endocrinol Diabetes. 2012;120(7):401-404. doi:10.1055/s-0032-1309008

  7. Menichella DM, Jayaraj ND, Wilson HM, et al. Ganglioside GM3 synthase depletion reverses neuropathic pain and small fiber neuropathy in diet-induced diabetic mice. Mol Pain. 2016;12:1744806916666284. doi:10.1177/1744806916666284

  8. Fineschi S, Klar J, Gustafsson KA, Jonsson K, Karlsson B, Dahl N. Inflammation and Interferon Signatures in Peripheral B-Lymphocytes and Sera of Individuals With Fibromyalgia. Front Immunol. 2022;13:874490. Published 2022 May 26. doi:10.3389/fimmu.2022.874490

  9. Skaper SD, Facci L, Zusso M, Giusti P. An inflammation-centric view of neurological disease: beyond the neuron [published correction appears in Front Cell Neurosci. 2020;13:578]. Front Cell Neurosci. 2018;12:72. doi:10.3389/fncel.2018.00072

  10. Jung C, Ichesco E, Ratai EM, et al. Magnetic resonance imaging of neuroinflammation in chronic pain: a role for astrogliosis? Pain. 2020;161(7):1555-1564. doi:10.1097/j.pain.0000000000001815

  11. Nijs J, Loggia ML, Polli A, et al. Sleep disturbances and severe stress as glial activators: key targets for treating central sensitization in chronic pain patients? Expert Opin Ther Targets. 2017;21(8):817-826. doi:10.1080/14728222.2017.1353603

  12. Bäckryd E, Tanum L, Lind AL, Larsson A, Gordh T. Evidence of both systemic inflammation and neuroinflammation in fibromyalgia patients, as assessed by a multiplex protein panel applied to the cerebrospinal fluid and to plasma. J Pain Res. 2017;10:515-525. doi:10.2147/JPR.S128508

  13. Zhang X, Hartung JE, Bortsov AV, et al. Sustained stimulation of β2- and β3-adrenergic receptors leads to persistent functional pain and neuroinflammation. Brain Behav Immun. 2018;73:520-532. doi:10.1016/j.bbi.2018.06.017

  14. Sommer C, Leinders M, Üçeyler N. Inflammation in the pathophysiology of neuropathic pain. Pain. 2018;159(3):595-602. doi:10.1097/j.pain.0000000000001122

  15. Seo S, Jung YH, Lee D, et al. Abnormal neuroinflammation in fibromyalgia and CRPS using [11C]-(R)-PK11195 PET. PLOS ONE. 2021;16(2):e0246152. doi:10.1371/journal.pone.0246152

  16. Ji RR, Nackley A, Huh Y, Terrando N, Maixner W. Neuroinflammation and central sensitization in chronic and widespread pain. Anesthesiology. 2018;129(2):343-366. doi:10.1097/ALN.0000000000002130

  17. Tennant F. Microglial modulators: a new therapeutic class. Pract Pain Manag.

  18. Liu CY, Wang X, Liu C, Zhang HL. Pharmacological targeting of microglial activation: new therapeutic approach. Front Cell Neurosci. 2019;13:514. doi:10.3389/fncel.2019.00514

  19. Camara ML, Corrigan F, Jaehne EJ, Jawahar MC, Anscomb H, Baune BT. Effects of centrally administered etanercept on behavior, microglia, and astrocytes in mice following a peripheral immune challenge. Neuropsychopharmacology. 2015;40(2):502-512. doi:10.1038/npp.2014.199

  20. Abd-Ellatief RB, Mohamed HK, Kotb HI. Reactive astrogliosis in an experimental model of fibromyalgia: effect of dexmedetomidine. Cells Tissues Organs. 2018;205(2):105-119. doi:10.1159/000488757

  21. Mueller C, Ness TJ, Younger JW. Low-dose dextromethorphan for the treatment of fibromyalgia pain: results from a longitudinal, single-blind, placebo-controlled pilot trial. J Pain Res. 2021;14:189-200. doi:10.2147/JPR.S285609

  22. D’Amico R, Fusco R, Siracusa R, et al. Inhibition of p2x7 purinergic receptor ameliorates fibromyalgia syndrome by suppressing nlrp3 pathway. Int J Mol Sci. 2021;22(12):6471. doi:10.3390/ijms22126471

  23. Royds J, Conroy MJ, Dunne MR, McCrory C, Lysaght J. An investigation into the modulation of T cell phenotypes by amitriptyline and nortriptyline. Eur Neuropsychopharmacol. 2020;31:131-144. doi:10.1016/j.euroneuro.2019.12.106

  24. Clinical Pain Advisor. Neuroinflammation: treating the underlying cause of chronic, severe pain.

  25. Johns Hopkins Medicine. Small fiber sensory neuropathy.

  26. MedlinePlus. Small fiber neuropathy.

  27. Oaklander AL, Nolano M. Scientific advances in and clinical approaches to small-fiber polyneuropathy: a review [published correction appears in JAMA Neurol. 2019;76(12):1520]. JAMA Neurol. 2019;76(10):1240-1251. doi:10.1001/jamaneurol.2019.2917

  28. Metyas S, Chen C, Quismorio A, Abdo N, Kamel K. Improvement of nerve fiber density in fibromyalgia patients treated with ivig. Curr Rheumatol Rev. 2020;16(4):280-284. doi:10.2174/1573397115666191106120622

  29. Yamanaka K, Takahashi Y, Azuma Y, Hantani Y. Assay development and screening for the identification of ganglioside gm3 synthase inhibitors. Biochemistry. 2020;59(12):1242-1251. doi:10.1021/acs.biochem.0c00055

Adrienne Dellwo

By Adrienne Dellwo

Dellwo was diagnosed with fibromyalgia in 2006 and has over 25 years of experience in health research and writing.


Leave a Reply

Your email address will not be published. Required fields are marked *

Copyright © All rights reserved. | Newsphere by AF themes.